methoxsalen


Also found in: Wikipedia.

methoxsalen

 [mĕ-thok´sah-len]
an acrylic acid compound that induces melanin production on exposure of the skin to ultraviolet radiation; used orally and topically in the treatment of idiopathic vitiligo, mycosis fungoides, and psoriasis.

methoxsalen

A photosensitising psoralen that is given systemically or topically before the skin is exposed to UV light, as part of treatment for psoriasis, eczema, vitiligo and some cases of cutaneous lymphoma.

methoxsalen

Oxsoralen® Dermatology A photosensitizing psoralen, given systemically or topically, after which the skin is exposed to UV light. See Psoriasis, PUVA.
References in periodicals archive ?
Mallinckrodt Pharmaceuticals, a leading global specialty pharmaceutical company, announced interim analysis results of its company-sponsored, Phase 3, single-arm, open-label, multi-center study assessing the efficacy of treating steroid-refractory, acute Graft-versus-Host Disease (aGvHD) pediatric patients with UVADEX (methoxsalen) Sterile Solution in conjunction with the THERAKOS CELLEX Photopheresis system.
Lange, "Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis," JAMA Dermatology, vol.
Pathak, "Part IV: basic considerations of the psoralens: historical aspects of methoxsalen and other furocoumarins 11 from the Division of Dermatology, University of Oregon Medical School, Portland, Oregon," Journal of Investigative Dermatology, vol.
Cases Sex Age Why the treatment (year-old) of PUVA was given 1(2) Female 45 Vitiligo 2(3) Male 50 Psoriasis 3(4) Male 80 Psoriasis 4(5) Female 57 Mycosis fungoides 5(6) Female 65 Psoriasis 6(7) Female 67 Psoriasis 7(8) Male 58 Psoriasis 8(9) Male 61 Psoriasis 9 (present Female 26 Mycosis fungoides case) Cases Type of UVA 1(2) Topical PUVASOL 2(3) Oral PUVA (methoxsalen) 3(4) Oral PUVA (5-MOP) 4(5) Oral PUVA (8-MOP) 5(6) Oral PUVA (8-MOP) 6(7) UVA 7(8) PUVA (unspecified) 8(9) Oral PUVA (oxsoralen) 9 (present Oral PUVA (8-MOP) case)
Similarly, methoxsalen, the main component of the aqueous extract of Poncirus trifoliata, inhibited AChE activity reducing memory loss and learning problems associated with a neurotoxicity in vivo model induced with trimethyltin [16].
Components Amount (%) S- ASR ASR 1 Butylphthalide 4.35 2.47 2 Pentadecane, 8-heptyl- 0.29 -- 3 Z-Butylidenephthalide 8.79 4.61 4 b-Eudesmol 0.13 -- 5 E-Butylidenephthalide 0.15 0.11 6 Senkyunolide A 3.14 2.43 7 Muurola-4,11-diene 0.14 0.08 8 Z-Ligustilide 49.8 41.5 9 1-Nonadecene 0.56 0.36 10 Cryptone 0.58 0.31 11 3,9-Diethyl-6-tridecanol 0.21 0.14 12 5-(2-Thienyl)-4-pyrimidinamine 0.19 0.13 13 g-Eudesmol 0.27 0.10 14 E-Ligustilide 8.30 4.55 15 6,7-Dihydroxyligustilide 0.12 0.09 16 Senkyunolide F 0.18 0.10 17 Hexadecanoic acid 0.01 -- 18 Senkyunolide H 0.12 0.04 19 Senkyunolide I 0.38 0.13 20 1-Octadecanol 0.20 -- 21 Methoxsalen 0.22 0.12 22 Marmesin 0.21 -- 23 Lomatin 0.70 0.53 (a) RRI: Related retention indices calculated against n-alkanes.
Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet A radiation.
Treatment of vitiligo with oral methoxsalen and UVA.
Comparison of trioxsalen bath and oral methoxsalen PUVA in psoriasis.
(21.) PUVA treatment in lichen planus: comparison of oral and external methoxsalen regimens.
M2 EQUITYBITES-February 16, 2012-Valeant Pharmaceuticals International Inc awarded FDA approval of additional manufacturer of methoxsalen for psoriasis(C)2012 M2 COMMUNICATIONS http://www.m2.com